Bipolar Medication Guide: Mood Stabilizers, Antipsychotics, and Antidepressant Cautions

Bipolar disorder is treated with medication. Not as a crutch, not as a bridge until therapy kicks in, and not as an optional supplement to lifestyle changes. Medication is the pharmacological foundation of bipolar care, and understanding what each class of medication does, and what it cannot do, is essential for anyone navigating this diagnosis.

The three major classes involved in bipolar treatment are mood stabilizers, atypical antipsychotics, and antidepressants. Each class has a distinct mechanism, a distinct clinical role, and a distinct risk profile. Getting this wrong, particularly with antidepressants, can significantly worsen the disorder’s course.

What Mood Stabilizers Actually Do

Mood stabilizers are the core pharmacological treatment for bipolar disorder. The term covers several distinct medications that share a common function: reducing the frequency and severity of manic and depressive episodes.

High-quality evidence supports using the class of medications known as mood stabilizers, including lithium, valproic acid, and antipsychotics as first-line pharmacological treatment that should be continued indefinitely because of the risk of patient relapse.

The major mood stabilizers each have a different strength profile:

Lithium. The oldest and most studied mood stabilizer. Lithium is the treatment of choice for classic euphoric mania and has proven antisuicidal properties. A large Swedish population study published in Lancet Psychiatry found that lithium was the only monotherapy associated with a reduced risk of hospitalization for both bipolar depression and mania, while antidepressant monotherapy was associated with a 22% increased risk of mania-related hospitalization. Lithium requires five days to achieve a steady state and needs regular blood monitoring because of its narrow therapeutic window. High lithium levels can be dangerous. Your prescriber will order blood tests at regular intervals to ensure levels stay in the therapeutic range.

Valproate (Depakote). Often used for acute mania because it can be titrated quickly. Valproic acid is effective for acute mania and is frequently used for rapid cycling presentations. It is associated with weight gain and, critically, carries significant teratogenic risk in pregnancy. Women of childbearing age must be counseled on this risk before starting valproate.

Lamotrigine (Lamictal). Lamotrigine may be the most effective mood stabilizer specifically for bipolar depression, but is less helpful for mania. Its titration must be very slow to minimize the risk of Stevens-Johnson syndrome, a rare but serious skin reaction. Lamotrigine is generally weight-neutral and has a favorable tolerability profile for many patients. Because of its antidepressant-dominant profile, it is frequently paired with lithium or an antipsychotic to provide broader spectrum coverage.

Carbamazepine (Tegretol). An anticonvulsant used for acute mania, particularly in patients who have not responded to lithium. It has significant drug interaction potential and requires blood monitoring.

Atypical Antipsychotics: The Expanding Role

Atypical antipsychotics are no longer considered supplementary medications in bipolar disorder. Several are FDA-approved as monotherapy for bipolar depression, mania, or both.

Quetiapine (Seroquel). FDA-approved for acute mania, bipolar depression, and as maintenance therapy. Quetiapine is one of the most frequently prescribed medications in bipolar disorder and has a substantial evidence base for both poles. It is sedating, which can be useful for sleep disruption during mania, but can also impair daytime functioning. Weight gain and metabolic effects are meaningful concerns with long-term use.

Lurasidone (Latuda). FDA-approved for bipolar I depression, both as monotherapy and as adjunctive therapy with lithium or valproate. Lurasidone has a more favorable metabolic profile than quetiapine and is less sedating, making it a preferred option when weight and metabolic risk are clinical considerations. It must be taken with food for proper absorption.

Cariprazine (Vraylar). FDA-approved for acute manic and mixed episodes and for bipolar I depression. Cariprazine’s D3 dopamine receptor activity may offer advantages for motivational and cognitive symptoms of bipolar depression.

Aripiprazole (Abilify). FDA-approved for acute mania and as maintenance therapy. Its partial dopamine agonism profile produces different side effects from other antipsychotics, with less sedation but potential for activation and akathisia (restlessness).

Atypical antipsychotics are frequently combined with mood stabilizers. Because mood stabilizers can be slow to reach full effect, an antipsychotic may be added during the acute phase to provide faster symptom control, with the antipsychotic potentially being tapered once the mood stabilizer reaches therapeutic levels.

The Antidepressant Question: Why Caution Is Essential

The most clinically consequential issue in bipolar pharmacology is the use of antidepressants. The evidence on this point is strong enough that it has been embedded in multiple major clinical guidelines, and understanding it can prevent serious harm.

Current guidelines do not endorse adjunctive antidepressants as a first-line treatment for acute bipolar depression and suggest avoiding monotherapy entirely in bipolar I disorder. The concern is treatment-emergent mania, the switch from a depressive episode into a manic or hypomanic one triggered by the antidepressant.

A Swedish national registry study of 3,240 patients with bipolar disorder found that antidepressant monotherapy was associated with a significantly increased risk of treatment-emergent mania (hazard ratio 2.83, 95% CI 1.12 to 7.19). Critically, no increased risk of mania was seen in patients receiving an antidepressant while also treated with a mood stabilizer.

The clinical implication is not that antidepressants can never be used in bipolar disorder. It is that:

1. They should not be used as monotherapy in bipolar I disorder.
2. When used, they should be combined with a mood stabilizer or antipsychotic.
3. They are more often appropriate for bipolar II disorder than bipolar I.
4. Patients with rapid cycling, mixed features, or a history of manic switch should receive antidepressants only with significant caution and close monitoring.

The ISBD Task Force consensus statement recommends that monotherapy with non-antidepressant drugs such as lithium, lamotrigine, quetiapine, and lurasidone should be considered before prescribing antidepressants to patients with bipolar depression.

The most dangerous clinical scenario is a patient who has unrecognized bipolar disorder, is prescribed an antidepressant for what appears to be unipolar depression, and experiences a first manic episode as a result. This is not rare. Many patients with bipolar disorder receive years of antidepressant-only treatment before the bipolar diagnosis is recognized.

Why Patients Stop and What It Costs Them

Bipolar medications can be difficult to tolerate. Lithium’s monitoring requirements, valproate’s weight gain, antipsychotics’ sedation and metabolic effects: these are real burdens that must be weighed against real benefits.

But stopping bipolar medication unilaterally carries a cost that most patients underestimate. Patients who stop taking their mood stabilizers because they feel well face significantly elevated risk of rapid relapse. Feeling stable is often a direct result of the medication. Stopping the medication removes the foundation of that stability.

The relapse risk after stopping bipolar medications is not gradual. It can be rapid. Manic episodes after antidepressant or antipsychotic discontinuation can arrive within weeks of stopping. The new episode is often more severe than those that preceded it.

This is why bipolar care requires ongoing monitoring, not just acute treatment. The question is not only whether the medication managed last week’s symptoms. It is whether the longitudinal pattern suggests that the current regimen is providing adequate protection, whether side effects are being caught and addressed before they drive discontinuation, and whether new episode warning signs are visible before they escalate.

What Monitoring Changes

Bipolar disorder has a treatment gap that is structurally similar to the adherence gap in unipolar depression, but with higher stakes. A patient who stops an antidepressant for unipolar depression faces relapse risk. A patient who stops a mood stabilizer for bipolar disorder faces relapse risk and, in many cases, the additional risk of a manic episode that is qualitatively different from what came before.

Between-visit monitoring changes this risk profile. When a prescriber can see mood trajectory, sleep patterns, and functional indicators across weeks rather than only at quarterly appointments, they can identify prodromal warning signs before a full episode develops. Manic episodes almost always have precursors: sleep reduction, increased energy, racing thoughts, decreased need for rest. These appear in daily check-in data before they appear in a clinical visit.

“Bipolar medication management is not a set-it-and-forget-it situation,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “The medications require monitoring, the doses require adjustment, and the warning signs of both depression and mania appear in between appointments, not during them. When I have daily data on how a patient is actually doing, I can see a pattern forming two weeks before it becomes an emergency. That is the difference between managing this illness and chasing it.”

What Members Are Saying

KS

K.S., 41

Bipolar I Disorder

“I had been on an antidepressant for three years before anyone told me it might be making things worse. My mood was cycling more frequently and I had one hospitalization. When I finally got a full evaluation and started lithium, the stability I achieved in four months was more than I had in years. No one had ever explained the antidepressant risk to me.”

PB

P.B., 29

Bipolar II Disorder

“I stopped my medication twice because I felt good and thought I did not need it anymore. Both times I relapsed within two months. My prescriber at Siggy was very clear: feeling good is not a reason to stop. It is evidence that the medication is working. That framing finally made it stick for me.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Bipolar disorder requires medication management across the full mood spectrum, not just during acute episodes. Mood stabilizers, primarily lithium, valproate, and lamotrigine, form the pharmacological foundation. Atypical antipsychotics address both mania and, increasingly, bipolar depression. Antidepressants require extreme caution and should not be used as monotherapy in bipolar I disorder given the evidence for mania induction.

The clinical goal is not only episode treatment. It is episode prevention, through a monitoring relationship that catches warning signs before they escalate into crises. That requires continuity of care, not quarterly appointments.

Managing a bipolar diagnosis takes a care team that follows you between visits, not just during them. Start your anonymous intake with SiggyMD, reviewed by a licensed psychiatrist, with daily check-ins that make the early warning signs visible before they become full episodes. You can also read about how medication adherence affects long-term outcomes across psychiatric conditions.

Sources

• Price AL, Marzani-Nissen GR. Bipolar Disorders: A Review. American Family Physician. 2021;103(4):227-239.

• Viktorin A, et al. The Risk of Switch to Mania in Patients With Bipolar Disorder During Treatment With an Antidepressant Alone and in Combination With a Mood Stabilizer. American Journal of Psychiatry. 2014;171(10):1067-1073.

• Nierenberg AA, et al. Diagnosis and Treatment of Bipolar Disorder: A Review. JAMA. 2023;330(14):1370-1380.

• CAMH. Mood Stabilizing Medications. Centre for Addiction and Mental Health. Accessed June 2026.

• Cleveland Clinic. Mood Stabilizers: What They Are, How They Work and Side Effects. Cleveland Clinic Health Library. Accessed June 2026.

• Goldberg JF, Truman CJ. Antidepressant-Induced Mania: An Overview of Current Controversies. Primary Care Companion to the Journal of Clinical Psychiatry. 2003;15(1):PCC.13r01556.

• American Journal of Psychiatry. Antidepressants and Bipolar Disorder: The Plot Thickens. Editorial. 2024.

• American Family Physician. Bipolar Disorders: Evaluation and Treatment. AFP. 2021;103(4):227-239.

• World Health Organization. Bipolar Disorder Fact Sheet. WHO. Accessed June 2026.